Harvard Medical School
Director of Translational Research in Allergy
Brigham and Women's Hospital
Boston, Massachusetts
Vice Chair of Clinical Affairs and Administration
Chief, Division of Rhinology and Endoscopic Sinus and Skull Base Surgery
Chief, Division of Allergy
Eastern Virginia Medical School
Norfolk, Virginia
Director, Allergy and Clinical Immunology Fellowship Program
National Jewish Health/University of Colorado
Denver, Colorado
Target Audience
The design of this activity addresses the needs of clinical immunologists/allergists, ear, nose, and throat (ENT) specialists, and pulmonologists who manage patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Program Overview
This Medical Jeopardy™ activity, led by our expert faculty, is designed to provide an informative and engaging approach to learning about CRSwNP! Topics covered include pathophysiology, assessment of phenotypes and disease burden, and the rationale and evidence behind available and emerging biologic therapies.
Learning Objectives
After completing this activity, the participant should be better able to:
- Discuss the roles of epithelial cytokine, including TSLP, in the pathogenesis of CRSwNP
- Comprehensively assess patients with CRSwNP for symptom burden, disease phenotypes, and effects on health-related quality of life
- Describe the clinical profiles of current and emerging biologic therapies for patients with CRSwNP
- Individualize treatment regimens for patients with CRSwNP based on symptoms, endotype, treatment goals, and comorbidities
Physician Accreditation Statement
Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Continuing Medical Education
Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the pretest, posttest, and program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Tanya M. Laidlaw, MD: Consulting Fees: AstraZeneca plc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Sanofi S.A.
Joseph K. Han, MD: Consulting Fees: AstraZeneca plc, GSK plc, Sanofi S.A.
Flavia Hoyte, MD: Consulting Fees: AstraZeneca plc, Genentech, Sanofi-Aventis U.S. LLC, Teva Pharmaceutical Industries Ltd., GSK; Contracted Research: Institution received research support from Genentech, Inc., Sanofi-Aventis U.S. LLC, GSK plc; Fees for Non-CE Services Received Directly From an Ineligible Entity or Their Agents: AstraZeneca plc, Genentech; Stock Shareholder: Amgen
The Integritas planners and managers have no relevant financial relationships with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is provided by Integritas Communications.
This activity is supported by an educational grant from AstraZeneca.
